Articles
Follicle Thought is pleased to announce a new company developing a treatment for androgenetic alopecia with an innovative technology. Unlike most other biotechs tackling the challenging field of hair regeneration, StimuSIL is a biomedical device company. Their team has created a completely new way to deliver photobiomodulation and incorporated it into a proprietary, patented hair…
Read More
A company working in protein degradation has entered the field of hair loss therapeutics in Spring 2023 with a new anti-hair loss drug. AH-001 AnHorn Medicines As I’ve stated before, we are in a new era for hair loss medication. Whereas in years past we would see a new therapy or company emerge once per…
Read More
An Indian drug-discovery startup with a focus on dermatology has unveiled its new website. Inovaugmet Research, which was mentioned in a recent article on Follicle Thought, is aiming to bring new therapies to unmet dermatological needs. Inovaugmet utilizes a dermatology-specific drug discovery platform called iNeu-3D screen to find new molecules. From the company’s website, iNeu-3D…
Read More
After a more thorough evaluation of FOL-005’s data from a phase 2 clinical trial, new management at Follicum believes that its drug candidate has a place in the treatment landscape for androgenic alopecia and they want to explain why. FOL-005 Phase 2 Results Revisited In February 2022, Follicum AB was acquired by Coegin Pharma, a…
Read More
On May 11, 2023, Kintor Pharmaceutical of China announced results from their US phase 2 trial testing KX-826 aka pyrilutamide in males with androgenetic alopecia. Successful Phase 2 Trial For US KX-826 Trial As is the trend for Kintor Pharmaceutical’s AGA programs, today’s announcement included positive results in a human trial. This milestone will help…
Read More
A new brief update has been shared about the official launch of the anticipated cosmeceutical CosmeRNA from the siRNAgen & Bioneer companies. CosmeRNA is a topical siRNA serum which inhibits the production of the androgen receptor protein using small interfering RNAs. It has been clinically tested in Korea, and Europe through the Dermatest agency and…
Read More
As we head into Q2 2023, the hair growth treatment industry continues to develop and make progress in various ways. Kintor Begins Phase 2 Trial For GT20029 Drug This news appeared one day following the publishing of this article. Kintor Pharmaceutical of China has dosed the first patient in a trial which will comprise 180…
Read More
Oral minoxidil is becoming an increasingly popular treatment option for hair loss patients. This article will discuss a few background points regarding this phenomenon. Low-Dose Oral Minoxidil For Hair Growth Over the past 3-4 years, the prescription and use of oral minoxidil for hair loss has increased. This trend was likely driven by several peer-reviewed…
Read More
The pool of biotechs which have expanded their sights into the hair regrowth field continues to grow in 2023. Inssen Multi-Targeted Affipep Technology Inssen is a Korean-based biotech company with Swedish roots, a bit of a rare combination. Its platform technology called “Affipep” combines novel affibody molecules with functional peptides to create selective therapeutics which…
Read More
The UCLA spinout with a focus on hair follicle stem cells has fully emerged into the public eye. Pelage Pharma PP405 More than six years in the making, Pelage Pharmaceuticals has an official website and an exciting drug candidate on its hands – PP405. Back in 2017, Drs. Bill Lowry and Heather Christofk of the…
Read More